6th Congress of the European Society of Vascular Medicine (ESVM)
1st National Congress of the Association for the study of Vascular Medicine in Spain (ASEMEVE)
IMPORTANT MESSAGE: Due to the Covid19 situation the 6th Congress of the European Society of Vasculas Medicine has been cancelled
Slovenia
Italy
Adriana Visonà reached her graduation in Medicine at the Faculty of Medicine of the University of Padua in 1979. She obtained medical specializations in Cardiology 1983, in Angiology 1986, and in Internal Medicine in 1991. She is Director of the Angiology Unit Azienda ULSS 2 Marca Trevigiana, Italy. She was Professor of Vascular Medicine at the Post Graduate School of Specialization in Angiology, Cardiology, Cardiosurgery and Internal Medicine at the University of Padua, and at the Master of Vascular Medicine, University of Padua.
Her clinical and research work is focused on arterial, venous and inflammatory vascular disease. She is author and co-author of 169 scientific articles of indexed international journals. She is Principal Investigators of Clinical trials Phase II, III, and Registries. She is Past president of Italian Society for Angiology and Vascular Medicine (SIAPAV) and European Society of Vascular Medicine (ESVM).
Czech Republic
Karel Roztocil is a vascular physician at the Institute of Clinical and Experimental Medicine in Prague, Czech Republic, where he is working for almost all his professional career. He served as Head of Department of Angiology and Deputy Head of Department of Cardiology. He is a member of several national and international cardiovascular scientific societies, active in organizing annual national meetings in the field of angiology.
In 2012 he chaired the 25th World Congress of the International Union of Angiology in Prague. He served as President of the Czech Society of Angiology (since 2000 until 2016), President of the Central European Vascular Forum, President of the International Union of Angiology and President of the European Society of Vascular Medicine (2018-19). He earned his PhD with thesis on the investigation of microcirculation in patients with different clinical conditions.
His research interests are focused mainly on the clinical pharmacology of vasoactive and antithrombotic drugs, the investigation of capillary permeability and microcirculation, and on clinical aspects of arterial and venous diseases. He is the author of 4 books, more than 450 publications in journals, and more than 750 oral communications on topics of angiology, phlebology and cardiology. He was awarded a Gold Medal of the Czech Medical Association in 2021 for services to medicine.
France
Isabelle Quéré is a Vascular Medicine physician and Professor of Vascular Medicine at Montpellier University, Montpellier, France. She is a founder member of the French Society of Vascular Medicine (SFMV) and member of the Executive Board.
She is a member of the ESVM and is representing the SFMV in the Executive Board. She is the treasurer of the ESVM.
Her medical background is in Internal Medicine and she then after qualified in Vascular Medicine. She is a full professor in Vascular Medicine. She has been running the Vascular Medicine departement of the Montpellier University Hospital since 2003.
The Vascular Medicine Department of Montpellier University Hospital is a referral centre for the management of peripheral arterial disease, venous thromboembolic disease and Vascular Rare diseases which include lymphatic and vascular anomalies including arterial fragility such as the Ehlers-Danlos syndrome. Identification of the genetics variants and personalized therapeutic developments are available for the Lymphatic pathologies. The centre is part of the RIETE Cohort study led by Pr Manuel Monreal on venous thromboembolic disease since the beginning of the project.
She joined a European Centre as a researcher dedicated to the identification of the genetic background of the Lymphatic anomalies including Primary Lymphoedema and became a director of the International Lymphoedema Framework in 2009. She is the President of the French ILF which is the Partenariat Français du Lymphoedème.
Reasearch areas of the Centre
– Venous thromboembolism (VTE) disease
– Lymphoedema and Vascular and Lymphatic anomalies
Publications
Venous thromboembolism (VTE) disease
Quéré I, Lamarti H , Chadefaux-Veckemans B. Thrombophilia, Homocystinuria and mutation of the factor V.
N Eng J Med 1996 ;4 :289-290.
Quéré I, Perneger TV, Zittoun J, Bellet H, Gris JC, Daurès JP, Schved JF, Mercier E, Dauzat M, Bounameaux H, Janbon C, de Moerloose P. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism. Lancet 2002; 359:747-52.
Righini M, Galanaud JP, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier MT, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenet C, Accassat S, Robert-Ebadi H, Carrier M, Le Gal G, Mermilllod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quéré I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016;3(12):e556-e562.
Jiménez D, Bikdeli B, Barrios D, Quezada A, Del Toro J, Vidal G, Mahé I, Quéré I, Loring M, Yusen RD, Monreal M; RIETE investigators Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. Int J Cardiol. 2018 Oct 15;269:327-333. doi: 10.1016/j.ijcard.2018.07.059. Epub 2018 Jul 17.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention Antithrombotic Therapy, and Follow-up: JACC State of the Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.PMID: 32311448
Lymphoedema and Vascular and Lymphatic anomalies
Burian EA, Karlsmark T, Franks PJ, Keeley V, Quéré I, Moffatt CJ. Cellulitis in chronic oedema of the lower leg: an international cross-sectional study. Br J Dermatol. 2021 Jan 6. doi: 10.1111/bjd.19803.
Quéré I, Stasi E, Mestre S, Roessler J, Roccatello D, Moffatt C. International Camps for Children with Lymphoedema and Lymphatic anomalies. When education links with Psychosocial Research. Lymphat Res Biol. 2021 Feb;19(1):36-40. doi: 10.1089/lrb.2020.0095.
Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus “off-label” therapy for vascular anomalies. Pediatr Blood Cancer. 2021 Feb 13:e28936. doi: 10.1002/pbc.28936.
Vignes S, Albuisson J, Champion L, Constans J, Tauveron V, Malloizel J, Quéré I, Simon L, Arrault M, Trévidic P, Azria P, Maruani A; French National Referral Center for Primary Lymphedema. Primary Lymphoedema French National Diagnosis and Care protocol (PNDS:Protocole National de Diagnostic et de Soins). Orphanet J Rare Dis. 2021 Jan 6;16(1):18. doi: 10.1186/s13023-020-01652-w
Quéré I, Nagot N, Vikkula M. Incidence of Cellulitis among Children with Primary Lymphedema. N Engl J Med. 2018 :24;378(21):2047-2048.
Amyere M, Revencu N, …,Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. Circulation. 2017 Sep 12;136(11):1037-1048.
Bessis D, Vernhet H, Bigorre M, Quéré I, Rössler J. Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus. JAMA Dermatol. 2016;152(9):1058-9
Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M; Lymphedema Research Group. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013;4(6):257-66.
Teaching
National Diploma of Vascular Medicine – DES
University Diploma of Lymphology, University of Montpellier : 70 hours teaching and 5 days training in hospital. 2003
Trans University Diploma on interventional endovenous treatment of the venous system (Grenoble, Rennes, Toulouse, Bordeaux, Nancy, Montpellier) : 2020
Hungary
Patrick CARPENTIER, MD, HDR is Professor Emeritus at the University of Grenoble – Alps, France, where he was Professor of Vascular Medicine (Exceptional Class) until September 2019. He is currently director of the La Lechere University Research Center. His research interests focus on clinical microcirculation, epidemiology of vascular diseases and rehabilitation of vascular diseases. He has authored more than 250 publications in peer-reviewed journals, founded the French Society of Vascular Medicine, is past-president of the European Society of Microcirculation and the International Union of Angiology and is currently honorary president of the European Society of Vascular Medicine.
Austria
Prof Marianne Brodmann, MD
Medical Specialist in Angiology and Internal Medicine Subsitute Head of Division of Angiology. Medical University of Graz, Austria.
Professor Marianne Brodmann is a Medical Specialist in Angiology and Internal Medicine at the Medical University of Graz, where she serves as Substitute Head of the Division of Angiology.
Prof Brodmann has been a member of multiple groups, such as Nucleus Working Group Peripheral Circulation of the ESC and Nucleus DVG (Dachverband Österreichische Gefäßmedizin) and Nucleus ÖGIA. She served as Secretary and Chairperson of the working Group Peripheral Circulation of ESC and was President of the ÖGIA from 2012-2014 and President of The European Society of Vascular Medicine (ESVM) from 2017-2018. She has also been a National Delegate of the International Union of Angiology (IUA) since 2005.
Prof Brodmann’s research interests include anticoagulation and thrombolysis, new endovascular technologies in the peripheral field, and evaluation of nature of restenosis. Additionally, Prof Brodmann has participated in multiple international clinical trials.
Belgium
Jean-Claude Wautrecht is currently Professor of the ULB (Université Libre de Bruxelles). He is Consultant at the Department of Vascular Diseases of the University Erasmus Hospital, ULB, Brussels, Belgium and at the Service of Cardiology of CHU Marie Curie Hospital, Lodelinsart, Belgium.
Before he established progressively a Medico-Surgical Department of Vascular Diseases at the University Erasmus Hospital from 1982. Also at the Erasmus Hospital, he was a member of the Board of the professional union of doctors from 1997 to 2004 and of the cooperation unit from 2014 to 2017.
He also developed a sector of angiology inside the Service of Cardiology at the CHU Charleroi from 1994.
He was invited professor at the Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Cameroon in 2012 and, at that time, contributed to the elaboration of a cardiovascular Department at the University Hospital of Douala.
He was Professor of Vascular Medicine at the Faculty of Medicine of the ULB from 2007 to 2017 and contributed as author or co-author to more than 90 publications in peer-reviewed journals. His main areas of interest are venous thromboembolic disease, vascular acrosyndromes, peripheral arterial disease, peripheral vascular ultrasound and defense of vascular medicine.
JC Wautrecht is currently the President of the UEMS (European Union of Medical Specialists) Division Angiology/Vascular Medicine and is a past-president of the BWGA (Belgian Working group on Angiology).
He is also member of the Board of the ESVM, of the VAS Foundation and of the CFPV (Collège Français de Pathologie Vasculaire).
Germany / United Kingdom
Prof. Christian Heiss is a clinical academic at the University of Surrey (Guildford) and practices Interventional Vascular Medicine at the Surrey and Sussex Healthcare NHS Trust and Nuffield Health. He is a Professor of Cardiovascular Medicine and head of Department of Clinical and Experimental Medicine and Treasurer of the Aorta and Peripheral Circulation working group of the European Society of Cardiology. His research interests include basic mechanisms of vascular homeostasis and human interventions for improvement of cardiovascular health and healthy aging. His clinical work focuses on the prevention and endovascular treatment of complex multi-level atherosclerosis.
Previously, Christian was a professor of Internal and Vascular Medicine at Düsseldorf University, Germany, and headed the Vascular Medicine Program in the Department of Cardiology, Pulmonology, and Vascular Medicine. He trained in basic cardiovascular research, interventional cardiology and vascular medicine. After medical school and dissertation at Düsseldorf University, he was a post-doctoral fellow in biochemistry & molecular biology, AHA research fellow (University of California San Francisco), and affiliated nutrition faculty (University of California Davis).
Christian represents the German Society of Vascular Medicine (Deutsche Gesellschaft für Angiologie) and UK Vascular Lipid and Metabolic Medicine Council of the Royal Society of Medicine on the ESVM board. He is also a member of the UEMS Division of Vascular Medicine/Angiology and nucleus member of the Aorta and Peripheral Circulation working group of the European Society of Cardiology. (See publications: https://www.ncbi.nlm.nih.gov/myncbi/1JmzFebqF6S/bibliography/public/) Twitter: #heissheissheiss
Greece
Ireland
Caitriona Canning MB, BCh, BAO, BEEAVM, RPVI.
After graduating from UCD, Caitriona Canning completed Vascular Surgery training and undertook a Clinical Fellowship in Vascular Medicine in the Cleveland Clinic, Ohio.
On her return, she was appointed to Trinity and St. James’s Hospital as an Associate Professor of Vascular Disease.
Her interests include venous disease, ulcers, limb swelling, prevention and arteriopathy (including Fibromuscular Dysplasia).
Poland
Prof. Agata Stanek, MD, PhD,
A specialist in internal diseases and angiology (vascular medicine), works at Department and Clinic of Internal Medicine, Angiology and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland (position: vice-Head); Director of Doctoral School of Medical University of Silesia; Regional Consultant in Angiology for Silesian Voivodeship; Member of the Regional Board for the Health Needs of the Silesian Voivodeship; Board Member at the Polish Society for Angiology; Member of the Medical Examination Board for specialty certificate in angiology.
France
Joel Constans succeeded Jill Belch at the head of the scientific committee of vascular medicine. He is professor of vascular medicine and head of the vascular medicine unit of Bordeaux University Hospital in France.
He was previously president of the Société Française de Médecine Vasculaire from 2010 to 2014. He was then president of the Collège des Enseignants de Médecine Vasculaire from 2014 to 2016 and head of the SFMV research group on microcirculation.
His research focused on clinical diagnosis of deep venous thrombosis, critical limb ischemia, and microcirculation, especially capillaroscopy and systemic sclerosis. He was author of 192 referenced publications.
Romania
Dan-Mircea Olinic, MD, Ph D
European angiologist and European cardiologist, Fellow of the European Society of Cardiology
Senior internist and cardiologist (Romania), Capacité d’Angiologie (France)
Professor, Medical Clinic no. 1, Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Head, Second Department of Cardiology (Interventional Cardiology and Cardiac Care Unit) and Cardiac Catheterization and Angiography Laboratory, Emergency University Hospital Cluj
Secretary, UEMS Division of Angiology and Chair, Board of the Exam for the European Diploma in Angiology
Co-Chair, Vascular ultrasound national training programme, Romania
Serbia
Bio coming soon!
Slovakia
Assoc. Prof. Juraj Madaric, MD, PhD – angiologist, cardiologist, president of Slovak Society of Angiology since 2017.
Head of Clinic of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia. Graduated at Faculty of Medicine, Comenius University Bratislava in 1997, after graduation working at National Institute of Cardiovascular Disease, Bratislava. Postgraduate education at Cardiovascular Center Aalst, Belgium (2003 – 2005), and at Dept. of Angiology, Heart Centrum Leipzig, Germany (2006 – 2007). Habilitated as Assoc. Professor at Comenius University Bratislava in 2015. His research and clinical interests are mainly peripheral artery disease, stem cells therapy, renal arteries, venous thromboembolism, aortic diseases, and carotid artery disease, endovascular interventions and vascular ultrasound.
Slovenia
Spain
Manuel Monreal is Full Professor of Vascular Medicine at the Faculty of Medicine, Universidad Autónoma in Barcelona, and also Head of Internal Medicine at the Hospital Universitari Germans Trias i Pujol in Barcelona, Spain, since 1983 to 2021.
Manuel Monreal has authored or co-authored more than 460 research articles on the study and treatment of venous thromboembolism in prominent journals including JTH, Chest, Circulation, JACC, Am f Med, Arch Intern Med and Thromb Haemost.
Manuel Monreal is Coordinator of the Registro Informatizado de la Enfermedad Trombo Embólica (RIETE) registry.
Sweden
Anders Gottsäter graduated as MD at Lund University, Sweden in 1986, qualified as specialist in Internal Medicine in 1992, and as PhD in Medicine in 1994. He served at the Department of Vascular Diseases, Skåne University Hospital in Malmö, Sweden 1994-2000, and is currently professor in Medicine at Lund University, Department of Medicine, Skåne University Hospital in Malmö.
Gottsäter is the author or co-author of around 235 scientific papers and 55 books or book chapters in the field of vascular disease, past Chairman of the Swedish Society of Vascular Medicine, and present board member of the European Society of Vascular Medicine.
Switzerland
Lucia Mazzolai, MD. Ph.D is a Professor of Vascular Medicine at the University of Lausanne, Switzerland where she is the head of the Angiology division and director of the Heart and Vessel Department. She is also currently the director of the malformation and rare vascular disease centre at the Lausanne University Hospital (CHUV). Her research interests are within the field of cardiovascular diseases with special reference to peripheral artery disease, evaluating the role of exercise, inflammation and risk prediction.
She also has an interest in Venous Thromboembolism and rare vascular diseases coordinating a registry aiming at understanding physiopathology and improving diagnosis and treatment. Professor Mazzolai authored more than 300 publications in peer-reviewed journals.
She is currently president-elect of the European Society of Vascular Medicine (ESVM) where she co-chairs the integrated pathway committee. Professor Mazzolai is also a member of the Working group pf Aorta and Peripheral Vascular Disease of the ESC of which she is the current chair. Professor Mazzolai serves in the editorial board of VASA. She was nominated to the ‘Forum des 100’ in 2018 (one hundred personalities who make up the French-speaking part of Switzerland).
Ukraine
United Kingdom
1979 – 10. 1985 Medical School, Technical University Aachen, Germany
DOCTOR’S THESIS
Department of History of Medicine, Prof. Dr. med. A. H. Murken
“The History of the health system and the traditional medicine
of the Caribbean island of Dominica ”
POSTDOCTORAL TRAINING
Thoracic and Cardiovascular Surgery
Director: Prof. Dr. med. B. J. Messmer
Internal Medicine, Cardiology
Directors: Prof. Dr. med. D. Larbig, Prof. Dr. med. H.-E. Reis
Cardiovascular Research
Chief: Jeffrey M. Isner, M.D.
Medical Clinic I
Directors: Prof. Dr. med. G. Riecker, Prof. Dr . med. G. Steinbeck
University Hospital, Westfälische Wilhelm University, Münster
Department of Cardiology and Angiology
Director: Prof. Dr. med. G. Breithardt
From 02. 2009 Head, Clinical and Interventional Angiology
Asklepios Clinic St. Georg, Hamburg
Campus Medical School Semmelweis University
CLINICAL ACCREDITATION
2006 and 2010 Accrediation for Vascular Medicine Training
HABILITATION
Habilitation in Internal Medicine
„Gene therapy for the prevention of restenosis following angioplasty“
ACADEMIC APPOINTMENTS
Ludwig Maximilian University, Munich, Germany
Westfälische Wilhelm University, Münster, Germany
Gustav-Carus University Dresden
(declined)
HEAD OF OWN RESEARCH GROUP since 7/1992
Major Research Fields
Atherosclerosis Research, including role of chlamydia
Pathophysiology of restenosis post-angioplasty
Gene and drug therapy for the prevention of restenosis
Gene therapy for the induction of angiogenesis
Cardiovascular local drug delivery
Regeneration of myocardium and vasculature (stem cell and cytokine therapy)
Funded by:
Deutsche Forschungsgemeinsacht (DFG)
Bundesministerium für Bildung und Forschung (BMBF)
Bayerische Staatsförderung
Ministerium für Wissenschaft und Forschung des Landes Nordrhein Westfalen
Friedrich-Baur-Stiftung
Ernst und Berta Grimmke-Stiftung:
Deutsche Stiftung für Herzforschung
Hans und Gertie Fischer-Stiftung
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Innovative Medizinische Forschung (IMF)
Principal Investigator
Several interventional and gene or cell therapy clinical trials
PAST-President European Society for Vascular Medicine (ESVM)
Research Foundations
Deutsche Forschungsgemeinschaft (DFG)
Deutsche Gesellschaft für Kardiologie, Herz- und Kreislaufforschung (DGK)
European Society of Cardiology (ESC)
Fonds zur Förderung der wissenschaftlichen Forschung (FWF)(Austrian Science Fund)
Innovative Medizinische Forschung (IMF)
Jubiläumsfond der Österreichischen Nationalbank
Leducq Foundation
Scientific Sessions of the American Heart Association (AHA)
The Wellcome Trust
Volkswagenstiftung
Sheffield Hospitals Charitable Trust
Swiss National Science Foundation
Health Research Board Irland
Journals
American Journal of Physiology – Cell Physiology
Arteriosclerosis, Thrombosis, Vascular Biology
Atherosclerosis
Basic Research in Cardiology
Biochemical Biophysical Research Communications
BioDrugs
Biomaterials
Blood Coagulation & Fibrinolysis
British Journal of Pharmacology
Cardiovascular Research
Cellular and Molecular Life Sciences
Circulation
Current Cardiology Reviews
Current Drugs
Current Medicinal Chemistry
Current Opinion in Biology
Dialogues
European Journal of Clinical Investigation
European Surgical Research
Gene Therapy
Haemostasis and Thrombosis
Heart and Vessels
Human Gene Therapy
International Journal of Clinical Rheumatology
Journal of the American College of Cardiology
Journal of Cellular Physiology
Journal of Endovascular Therapy
Journal of Gene Medicine
Journal of Molecular Medicine
Journal of Molecular and Cellular Cardiology
Journal of Leukocyte Biology
Molecular Therapy
Nature Medicine
Proteomics
Recent Patents
Stem Cells and Development
Transplant Immunology
VASA
Zeitschrift für Kardiologie
EDITORIAL BOARD
Current Opinion in Molecular Therapeutics
Kardiologie Assistenz
Recent Patent Reviews
VASA
Current Cardiology Reviews
Journal of Angiogenesis Research
CLINICAL TRIALS
Coordinator: CAVEAT I
CAVEAT II
BIOGEN
ARTS I
Principal Investigator: Cardialysis
ARTS II
Bayer Vital
Eurocanal, COMPASS
Novartis
Arteriosklerose Antikörper
Astra Zeneca
EUCLID
Biotronic
Register PACE
Bard
Lutonix
Investigator-initiated:
ICE
Gene therapy trials in patients with therapy-refractory angina:
Vascular Genetics Inc. /Cato Research
VEGF2-CAD-CL-001, VEGF2-CAD-CL-003
VEGF2-CAD-CL-002E, VEGF2-CAD-CL-002F, VEGF2-CAD-CL-002ET
VEGF-CAD-CL-007E, VEGF2-CAD-CL-007EF
Cordis/GenVec
Phase II AdVEGF121 (NOVA)
Gene therapy trials in patients with PAD:
Vascular Genetics Inc. /Cato Research
VEGF2-PAD-CL-003
VEGF2-PAD-CL-006, VEGF2-PAD-CL-010, VEGF2-PAD-CL-009
VEGF2-PAD-CL-002
Aventis/Gencell-Centelion/Sanofi-Aventis
Phase II NV1FGF-PM201 (TALISMAN 201)
Phase II NVFGF-PM211 (TALISMAN 211)
Phase III TAMARIS
Schering
Phase II Ad1FGF-1
Genzyme
Phase II PADHIF00704 (WALK study)
Phase II PADHIF00704 (CLI study)
Cell therapy trials in patients with cardiomyopathy
Investigator-initiated
G-CSF, in Kooperation mit der Universität Essen
Cell therapy trials in patients with PAD
Pluristem
Phase III CLI (Horizon 2020 PACE Projekt)
Phase III Claudication
ReNeuron
Phase I PAD, Phase II CLI
Prizes
1.
Finalist Young Investigator Posters 66th. Congress of the European Atherosclerosis Society, 7. 1996, Florence, Italy
Nikol S, Huehns TY, Esin S, Mrochen S, Engelmann MG, Schirmer J, Günzburg WH, Höfling B. Local gene transfer of the antisense senescent cell-derived Inhibitor 1 (SDI) delivered with the needle injection catheter induces neointimal formation. Proceedings of the European Atherosclerosis Society. p64, 1996
2.
Best presentation Annual Meeting of the German Society of Atherosclerosis Research (DGAF), 3. 1997, Blaubeuren
Nikol S, Huehns TY, Krauß E, Esin S, Mrochen S, Engelmann MG, Schmid M, Günzburg WH, Höfling B. Adventitial gene transfer of the antisense to senescent cell-derived inhibitor 1 results in increased neointima. Jahrestagung der DGAF, 9.-11.3. 1997, Blaubeuren
3.
Best poster: Hans-Jürgen-Bretschneider Poster prize 2003 of the German Society of Cardiology and Cardiovascular Research, 10. 2003, Münster
Pelisek J, Fuchs A, Engelmann M, Golda A, Rolland P, Nikol S. Vascular endothelial growth factor response in porcine coronary and peripheral arteries using non-surgical occlusion model, local delivery and liposome-mediated gene transfer. Abstract Zeitschrift für Kardiologie.
4.
Fritz-Linder prize of the German Society of Surgery, 4. 2005, München
Kühnl A, Pelisek J, Rolland P, Nikol S. Der liposomale Gentransfer von C-natriuretischem Peptid (CNP) verhindert die Bildung von Neointima und fördert das Wachstum von Endothelzellen. Chirurgisches Forum Band 34:1-2, 2005
5.
Schwarz Monheim prize of the German Society of Angiology, 9. 2005, Berlin
Kühnl A, Pelisek J, Fuchs A, Mekkaoui C, Rolland PH, Nikol S. Local liposome-mediated gene transfer of C-type natriuretic peptide inhibits constrictive remodeling in balloon dilated porcine renal arteries. Abstracts VASA
6.
Prize fort the best M.D. thesis of the Heart Center, 2. 2008, Münster
Golda A, Pelisek J, Klocke R, Engelmann MG, Rolland PH, Mekkaoui C, Nikol S. Small poly-L-lysines improve cationic lipid-mediated gene transfer in vascular cells in vitro and in vivo. J Vasc Res. 44(4):273-82, 2007
7.
Prize for the best M.D. thesis of the Westfälischen Wilhelms-Universität Münster, 1. 2009, Münster
Scobioala S, Klocke R, Kuhlmann M, Tian W, Hasib L, Milting H, Eisenacher M, El-Banayosy A, Tenderich G, Schmidt O, König S, Michel G, Breithardt G, Nikol S. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. FASEB J. 22(4):1021-1031, 2008
108 Publications in PUBMED
Original publications including case reports
Minale C, Lambertz H, Nikol S, Messmer BJ. (New developments for reconstruction of the tricuspid valve). Neuentwicklung für die Rekonstruktion der Trikuspidalklappe. Helvetica Chirurgica Acta. 54:295-301, 1987
Minale C, Hollweg G, Nikol S, Mittermayer C, Messmer BJ. Closure of the pericardium using expanded Polytetrafluorethylene Gore-Tex-Surgical Membrane: Clinical experience. The Thoracic and Cardiovascular Surgeon. 35:312-315, 1987
Nikol S, Messmer BJ. Nichtcardiogenes Lungenödem als Folge der Heparinantagonisierung mit Protaminchlorid nach Cardiopulmonalem Bypass. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie. 2:40-42, 1988
Nikol S, Minale C, Messmer BJ. Interposition of coral between sternal blades to prevent postoperative dehiscence: A new method. Annals of Thoracic Surgery. 45:694-696, 1988
Minale C, Nikol S, Zander M, Uebis R, Effert S, Messmer BJ. Coronary endarterectomy: An old technique and new controversies. Advances in Cardiology. 36:34-40, 1988
Minale C, Lambertz H, Nikol S, Messmer BJ. Mittelfristige klinische und hämodynamische Ergebnisse einer neuen Technik zur Rekonstruktion der Trikuspidalklappe. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie. 2:157-161, 1988
Minale C, Nikol S, Hollweg G, Mittermayer C, Messmer BJ. Clinical experience with expanded Tetrafluorethylene Gore-Tex-Surgical Membrane: Clinical study of 110 cases. Journal of Cardiac Surgery. 3:193-201, 1988
8.
Minale C, Nikol S, Zander M, Uebis R, Effert S, Messmer BJ. Controversial aspects of coronary endarterectomy. Annals of Thoracic Surgery. 48:235-241, 1989
Nikol S, Minale C, Messmer BJ. New site for pacemaker generators in children. European Journal of Cardiothoracic Surgery. 4:342-344, 1990
Minale C, Lambertz H, Nikol S, Gerich N, Messmer BJ. Selective annuloplasty of the tricuspid valve. Two-year experience. The Journal of Thoracic and Cardiovascular Surgery. 99:846-851, 1990
Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-ß1 is increased in human vascular restenosis lesions. The Journal of Clinical Investigation. 90:1582-1592, 1992
Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM. Percutaneous arterial gene transfer in a rabbit model: Efficiency in normal and balloon-dilated atherosclerotic arteries. The Journal of Clinical Investigation. 90:936-944, 1992
Nikol S, Weir L, Sullivan A, Sharaf B, White CJ, Zemel G, Hartzler G, Stack R, Leclerc G, Isner JM. Persistently increased expression of the transforming growth factor-ß gene in human vascular restenosis. Analysis of 62 patients with one or more episodes of restenosis. Cardiovascular Pathology. 3:57-64, 1994
Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. American Journal of Pathology. 144:962-974,1994
Isner JM, Kearney M, Bauters C, Leclerc G, Nikol S, Pickering JG, Riessen R, Weir L. Use of human tissue specimens obtained by directional atherectomy to study restenosis. Trends in Cardiovascular Medicine. 4:213-221, 1994
Köster R, Windstetter U, Überfuhr P, Baumann G, Nikol S, Höfling B. Enhanced migratory activity of vascular smooth muscle cells with high expression of platelet-derived growth factor A and B. Angiology. 46:99-106,1995
Pahl C, Gonschior P, Huehns TY, Schrittenloher PK, Abels C, Nikol S, Höfling B. Uptake of benzoporphyrin derivative by cultured myofibroblasts: Possible use in restenosis prevention. Lasermedizin. 12:65-69, 1996
Nikol S, Huehns TY, Pilz G, von Scheidt W. Immune complex allergic vasculitis in association with the development of transverse myelitis – a case report. Angiology. 47:1107-11, 1996
Oswald H, Heinemann F, Nikol S, Günzburg WH. An inhibitor of marker enzyme activity in artery extracts that can be removed by chelating agents. Biotechniques. 22(1):78-81,1997
Nikol S, Murakami N, Pickering JG, Donovan C, Leclerc G, Höfling B, Isner JM, Weir L. Differential expression of nonmuscle myosin II isoforms in human atherosclerotic plaque. Atherosclerosis. 130:71-85, 1997
Mrochen S, Klein D, Salmons B, Nikol S, Smith JR, Günzburg WH. Inducible expression of p21 SDI-1 from a promoter conversion retroviral vector: a potential strategy for anti-proliferative gene therapy. Journal of Molecular Medicine. 75:820-828, 1997
22.
Nikol S, Kiefmann R, Huehns TY, Höfling B. Excessive arterial thrombus in spherocytosis. Angiology. 48:743-748, 1997
23.
Nikol S, Krauß E, Mrochen S, Schmid M, Engelmann MG, Schrittenloher PK, Günzburg WH, Höfling B. Neointimabildung nach Gefäßdilatation und transluminalem adventitiellem Gentransfer. In: H. Heinle, H. Schulte, G. Siegel (Eds.) Adhäsionsmoleküle, Zytokine und Apoptose bei der Gefäßumgestaltung. W. Kohlhammer, Stuttgart. 88-93, 1997
Nikol S, Huehns TY, Pilz G, von Scheidt W. Conservative treatment of a paracardial abscess following post-infarct patch grafting. The Scandinavian Journal of Thoracic and Cardiovascular Surgery. 32:49-50, 1998
25.
Nikol S, Höfling B, Wilbert-Lampen U, Klingel K, Samtleben W, König G, Steinbeck G. 51jähriger Patient mit reversiblen Infarkt-ähnlichen EKG-Veränderungen. Der Internist. 39:208-213,1998
26.
Nikol S, Esin S, Nekolla S, Huehns TY, Schirmer J, Schwaiger M, Höfling B. Use of nuclear magnetic resonance imaging angiography to follow up arterial remodeling in an animal model. Angiology. 49:251-258, 1998
Nikol S, Huehns TY, Weir L, Wight TN, Höfling B. Restenosis in human vein bypass grafts. Atherosclerosis. 139:31-39, 1998
28.
Nikol S. 51jähriger Patient mit reversiblen Infarkt-ähnlichen EKG-Veränderungen (Antwort auf Leserbrief). Der Internist. 39:892,1998
29.
Huehns TY, Krauß E, Mrochen S, Schmid M, Esin S, Engelmann MG, Schrittenloher PK, Günzburg WH, Höfling B, Nikol S. Neointimal growth can be influenced by local adventitial gene delivery via a needle injection catheter. Atherosclerosis. 144:135-150, 1999
30.
Armeanu S, Hässler I, Engelmann MG, Saller R, Salmons B, Nikol S. In vivo retroviraler Gentransfer in glatte Gefäßmuskelzellen mittels Implantation verkapselter Verpackungszellen. In: H. Heinle, H. Schulte, M. Hanefeld (Eds.) Atherogenese und Metabolisches Syndrom. Deutsche Gesellschaft für Arterioskleroseforschung. W. Kohlhammer, Stuttgart. 119-123, 1999
31.
Nikol S, Huehns TY, Krauß E, Armeanu S, Engelmann MG, Winder D, Salmons B, Höfling B. Needle Injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Therapy. 6:737-748, 1999
32.
Nikol S, Pelisek J, Engelmann MG, Rolland PH, Armeanu S. Prevention of restenosis using the gene for cecropin complexed with DOCSPER liposomes under optimized conditions. International Journal of Angiology. 9(2): 87-94, 2000.
33.
Armeanu S, Pelisek J, Krausz E, Fuchs A, Groth D, Curth R, Keil O, Quilici J, Rolland PH, Reszka R, Nikol S.. Optimization of non-viral gene transfer of vascular smooth muscle cells in vitro and in vivo. Molecular Therapy. 1:366-375, 2000.
34.
Pelisek J, Armeanu S, Nikol S. Evaluation of beta-galactosidase activity in the presence of blood. Journal of Vascular Research. 37:585-593, 2000.
35.
Pelisek J, Armeanu S, Nikol S. Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors. Cell Proliferation. 34:305-320, 2001.
Nikol S, Armeanu S, Engelmann MG, Pelisek J, Fuchs A, Zähringer C, Bartoli JM, Th. Mesana, P.H. Rolland. Evaluation of endovascular techniques to create a porcine femoral artery occlusion model. Journal of Endovascular Therapy. 8:401-407, 2001.
37.
Armeanu S, Hässler I, Saller R, Heinemann F, Stange J, Engelmann MG, Krausz E, Salmons B, Nikol S. In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer. Journal of Microencapsulation. 18:491-506, 2001.
38.
Pelisek J, Engelmann MG, Golda A, Fuchs A, Armeanu S, Shimizu M, Mekkaoui C, Rolland PH, Nikol S. Optimisation of non-viral transfection: variables influencing liposome-mediated gene transfer in proliferating versus quiescent cells in culture and in vivo using a porcine restenosis model. Journal of Molecular Medicine. 80:724-736, 2002.
39.
Nikol S, Engelmann MG, Pelisek J, Fuchs A, Golda A, Shimizu M, Mekkaoui C, Rolland PH. Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs. Acta Physiologica Scandinavica. 176:151-159, 2002.
40.
Nikol S, Pelisek J, Engelmann MG, Shimizu M, Fuchs A, Golda A, Armeanu S, Mekkaoui C, Rolland PH. Vascular endothelial growth factor (VEGF165) appears to have a district-specific influence on arteries of distinct developmental origin resulting in angiogenesis versus arteriogenesis in different vascular beds. Journal of Endovascular Therapy. 9:842-834, 2002.
41.
Pelisek J, Fuchs A, Engelmann MG, Shimizu M, Golda A, Mekkaoui C, Rolland PH, Nikol S. Vascular endothelial growth factor response in porcine coronary and peripheral arteries using non-surgical occlusion model, local delivery and liposome-mediated gene transfer. Endothelium.10:247-55, 2003.
42.
Engelmann MG, Shimizu M, Pelisek J, Fuchs A, Golda A, Mekkaoui C, Fraunberger P, Rolland PH, Nikol S. Comparison of surgical versus endovascular occlusion models in pig femoral arteries. Journal of Endovascular Therapy. 11:71-79, 2004.
43.
Middendorf K, Göhring P, Huehns TY, Seidel D, Steinbeck G,. Nikol S. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: Investigation of 507 patients with myocardial infarction. American Heart Journal. 147:897-904, 2004.
44.
Engelmann MG, Nikol S, Vogelmeier C. Pulmonary abscess with bacteremia in a young man. Canadian Medical Association Journal. 171(3):233, 2004.
45.
Engelmann MG, Redl CV, Nikol S. Recurrent perivascular inflammation induced by lipopolysaccharide (endotoxin) results in the formation of atheromatous lesions in vivo. Laboratory Investigation. Epub. 16. Feb. 2004. 84(4):425-432, 2004.
46.
Pelisek J, Kühnl A, Fuchs A, Walker GF, Rolland PH, Mekkaoui C, Ogris M, Wagner E, Nikol S. Functional analysis of C-type natriuretic peptide gene in vascular cells. Arteriosclerosis Thrombosis Vascular Biology. Juli 2004 epub. 24(9):1646-1651, 2004.
47.
Kühnl A, Pelisek J, Fuchs A, Mekkaoui C, Rolland PH, Nikol S. Local liposome-mediated gene transfer of C-type natriuretic peptide inhibits constrictive remodeling in balloon dilated porcine renal arteries. Journal Endovascular Therapy. 12:171-182, 2005.
48.
Pelisek J, Gaedtke L, DeRouchey J, Walker GF, Nikol S, E. Wagner. Optimized lipopolyplex formulations for gene transfer to human colon carcinoma cells under in vitro conditions. Journal of Gene Medicine. 8:186-197, 2006.
49.
Hüttmann A, Dührsen U, Stypmann J, Noppeney R, Nückel H, Neumann T, Gutersohn A, Nikol S, Erbel R. Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure: feasibility, safety and effects on exercise tolerance and cardiac function. Basic Research in Cardiology. 101:78-86, 2006.
Kuhlmann M*; Kirchhof P*, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S. G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med. 203:87-97, 2006.
Commentary in J Exp. Med. 203 (1), 2006: Heart cells keep the rhythm
Pelisek J, Fuchs AT, Kühnl A, Tian W, Kuhlmann M, Rolland PH, Mekkaoui C, Gaedtke L, Nikol S. C-Type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration. Journal of Gene Medicine. 8:186-197, 2006.
52.
Deiner C, Schwimmbeck PL, Koehler IS, Loddenkemper C, Noutsias M, Nikol S, Schultheiss HP, Yla-Herttuala S, Pels K. Adventitial VEGF(165) gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries. Atherosclerosis. 189:123-132, 2006
53.
Engelmann MG, Redl CV, Pelisek J, Barz C, Heesemann J, Nikol S. Chronic perivascular inoculation with Chlamydophila pneumoniae results in plaque formation in vivo. Laboratory Investigation. 86:467-476, 2006.
54.
Tian W, Kuhlmann M, Pelisek J, Quang TH, Hasib L, Scobioala S, Klocke R, Nikol S. Paclitaxel delivered to adventitia attenuates neointima formation without compromizing re-endothelialization after angioplasty in a porcine restenosis model. Journal of Endovascular Therapy. 13:616–629, 2006.
55.
Golda A, Pelisek J, Klocke R, Rolland PH, Mekkaoui C, Nikol S. Small poly-L-lysines improve cationic lipid-mediated gene transfer in vascular cells in vitro and in vivo. Journal of Vascular Research. 44:273-282, 2007.
56.
Scobioala S, Klocke R, Kuhlmann M, Tian W, Hasib L, Milting H, Eisenacher M, El-Banayosy A, Tenderich G, Schmidt O, König S, Michel G, Breithardt G, Nikol S. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. FASEB J. 22(4):1021-1031, 2008
57.
Fuchs AT, Kuehnl A, Pelisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S. Inhibition of restenosis formation without compromising re-endothelialization as a potential solution to thrombosis following angioplasty ? Endothelium, 15:85-92, 2008.
58.
Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F on behalf of the TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Molecular Therapy, 16:972-978, 2008.
Fuchs AT, Kuehnl A, Pelisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S. Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent or angioplasty. Endothelium. 15:93-100, 2008.
60.
Sevimli S, Diederich K, Strecker JK, Schilling M, Klocke R, Nikol S, Kirsch F, Schneider A, Schäbitz WR. Endogenous brain protection by granulocyte-colony stimulating factor after ischemic stroke. Exp Neurol. 217(2):328-335, 2009.
61.
Diederich K, Sevimli S, Dörr H, Kösters E, Hoppen M, Lewejohann L, Klocke R, Minnerup J, Knecht S, Nikol S, Sachser N, Schneider A, Gorji A, Sommer C, Schäbitz WR. The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice. J Neurosci. 29(37):11572-81, 2009.
62.
Strecker JK, Sevimli S, Schilling M, Klocke R, Nikol S, Schneider A, Schäbitz WR. Effects of G-CSF treatment on neutrophil mobilization and neurological outcome after transient focal ischemia. Exp Neurol. 222(1):108-113, 2010.
63.
Kastrup J, Jørgensen E, Fuchs S, Nikol S, Bøtker HE, Gyöngyösi M, Glogar D, Kornowski R. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention. 6:813-818, 2011.
64.
Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E; TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011;377:1929-37.
65.
Van Belle E, Nikol S, Norgren L, Baumgartner I, Driver V, Hiatt WR, Belch J. Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2011;42:365-73.
66.
Milberg P, Klocke R, Frommeyer G, Quang TH, Dieks K, Stypmann J, Osada N, Kuhlmann M, Fehr M, Milting H, Nikol S, Waltenberger J, Breithardt G, Eckardt L. G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis, angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure. Basic Res Cardiol. 2011;106:995-1008.
67.
Niebuhr A, Henry T, Goldman J, Baumgartner I, van Belle E, Gerss J, Hirsch AT, Nikol S. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease. Gene Ther. 2012;19:264-270.
68.
Milberg P, Pott C, Frommeyer G, Fink M, Ruhe M, Matsuda T, Baba A, Klocke R, Quang TH, Nikol S, Stypmann J, Osada N, Müller FU, Breithardt G, Noble D, Eckardt L. Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm. 2012; 9:570-578
69.
Mooren FC, Völker K, Klocke R, Nikol S, Waltenberger J, Krüger K. Exercise delays neutrophil apoptosis by a G-CSF dependent mechanism. J Appl Physiol. 2012;113:1082-1090.
70.
Schulte KL, Amendt K, Hoffmann U, Tiefenbacher C, Weiss T, Mudra H, Hardung D, Nikol S. [Curriculum for interventional therapy for arterial diseases. Clinical competence for execution of catheter-based interventions on the arteries of the extremities, on the pelvic, visceral and renal arteries, on the extracranial arteries supplying the brain, and on dialysis shunts]. Vasa. 2012; 41:463-476.
71.
Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Diamantopoulos E, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Gallino A, Jaeger KA, Fitzgerald P, Colgan MP. Requirements for angiology/vascular medicine. Int Angiol. 2013 Dec;32(6):608-12.
71.
Schulte KL, Amendt K, Hoffmann U, Tiefenbacher C, Weiss T, Mudra H, Hardung D, Nikol S.. Curriculum Interventionelle Therapie der arteriellen Gefäßerkrankungen. Kardiologe 2012 · 6:375–389
72.
Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Diamantopoulos E, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Gallino A, Jaeger KA, Fitzgerald P, Colgan MP. Requirements for angiology/vascular medicine. Int Angiol. 2013 Dec;32(6):608-12.
73.
Kim J, Eligehausen S, Stehling M, Nikol S, Ko K, Waltenberger J, Klocke R. Generation of functional endothelial-like cells from adult mouse germline-derived pluripotent stem cells. Biochem Biophys Res Commun. 2014;443(2):700-5.
Krüger K, Klocke R, Kloster J, Nikol S, Waltenberger J, Mooren FC. Activity of daily living is associated with circulating CD34+/KDR+ cells and granulocyte colony-stimulating factor levels in patients after myocardial infarction. J Appl Physiol (1985). 2014; 1;116(5):532-7.
75.
Prokosch V, Stupp T, Spaniol K, Pham E, Nikol S. Angiogenic gene therapy does not cause retinal pathology. J Gene Med. 2014;16(9-10):309-16.
76.
Kirchhof P, Tal T, Fabritz L, Klimas J, Nesher N, Schulte JS, Ehling P, Kanyshkova T, Budde T, Nikol S, Fortmueller L, Stallmeyer B, Müller FU, Schulze-Bahr E, Schmitz W, Zlotkin E, Kirchhefer U. First report on an inotropic peptide activating tetrodotoxin-sensitive, “neuronal” sodium currents in the heart. Circ Heart Fail. 2015;8(1):79-88.
77.
Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Dimakakos EP, Marakomichelakis GE, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Amann-Vesti B, Gallino A, Fitzgerald P, Colgan MP. UEMS training requirements for angiology/vascular medicine european standards of postgraduate medical specialist training (ETR Document). Int Angiol. 2016;35(2):217-231.
78.
Fowkes FG, Forster R, Levin CE, Naidoo NG, Roy A, Shu C, Spertus J, Fang K, Bechara-Zamudio L, Catalano M, Visona A, Nikol S, Fletcher JP, Jaff MR, Hiatt WR, Norgren L; (TASC) on behalf of the Inter-Society Consensus for the Management of Peripheral Arterial Disease. Prioritisation of treatments for lower extremity peripheral artery disease in low- and middle-income countries. Int Angiol. 2017;36:203-215.
79.
Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P. [Treatment and Secondary Prevention of Venous Thromboembolism – Change in Oral Anticoagulation]. Dtsch Med Wochenschr. 2017 Jul;142(13):986-993. doi: 10.1055/s-0042-124132.
80.
Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40.
81.
Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, Baumgartner I, Diehm N, Nickling E, Müller-Hülsbeck S, Schmiedel R, Torsello G, Hochholzer W, Stelzner C, Brechtel K, Ito W, Kickuth R, Blessing E, Thieme M, Nakonieczny J, Nolte T, Gareis R, Boden H, Sixt S. Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1694-1704.
82.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ,
Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330.
83.
Belch J, Carlizza A, Carpentier PH, Constans J, Khan F, Wautrecht JC, Visona A, Heiss C, Brodeman M, Pécsvárady Z, Roztocil K, Colgan MP, Vasic D, Gottsäter A, Amann-Vesti B, Chraim A, Poredoš P, Olinic DM, Madaric J, Nikol S, Herrick AL, Sprynger M, Klein-Weigel P, Hafner F, Staub D, Zeman Z. ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon. Vasa. 2017 Oct;46(6):413-423.
84.
Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O’Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32458-3. Erratum in: Lancet. 2017 Dec 21
85.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O’Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32409-1.
86.
Norgren L, Weiss N, Nikol S, Hinchliffe RJ, Lantis JC, Patel MR, Reinecke H, Ofir R, Rosen Y, Peres D, Aberman Z. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial. Eur J Vasc Endovasc Surg. 2019 Apr;57(4):538-545.
87.
Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay JF, Ricco JB, Debus ES, Mazzolai L, Bauersachs R, Verhamme P, Bosch J, Nikol S, Nehler M, Aboyans V, Violi F. Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thromb Haemost. 2019 Apr;119(4):576-585.
88.
Lichtenberg M, Breuckmann F, Kramer V, Betge S, Sixt S, Hailer B, Nikol S, Arjumand J, Wittenberg G, Teßarek J, Nolte-Ernsting C. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions – the BIOFLEX PEACE All-Comers Registry. Vasa. 2019 Mar 29:1-8.
89.
Russell KS, Yates DP, Kramer CM, Feller A, Mahling P, Colin L, Clough T, Wang T, LaPerna L, Patel A, Lawall H, Shennak MM, Fulmer J, Nikol S, Smith WB, Müller OJ, Ratchford EV, Basson CT. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. Vasc Med. 2019 Oct;24(5):414-421.
90.
Frank U, Nikol S, Belch J. 5 Conservative treatment for PAD – Risk factor management. Vasa. 2019 Oct 3:1-12.
91.
Frank U*, Nikol S*, Belch J*, Boc V, Brodmann M, Carpentier PH, Chraim A, Canning C, Dimakakos E, Gottsäter A, Heiss C, Mazzolai L, Madaric J, Olinic DM, Pécsvárady Z, Poredoš P, Quéré I, Roztocil K, Stanek A, Vasic D, Visonà A, Wautrecht JC, Bulvas M, Colgan MP, Dorigo W, Houston G, Kahan T, Lawall H, Lindstedt I, Mahe G, Martini R, Pernod G, Przywara S, Righini M, Schlager O, Terlecki P. ESVM Guideline on peripheral arterial disease. Vasa. 2019 Sep;48(Suppl 102):1-79.
* all 3 authors contributed equally
92.
Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, Katsanos K, Mills JL, Nikol S, Reekers J, Venermo M, Zierler RE, Schaper NC. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). International Working Group on the Diabetic Foot (IWGDF). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3276.
Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, Katsanos K, Mills JL, Nikol S, Reekers J, Venermo M, Zierler RE, Schaper NC, Hinchliffe RJ. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: A systematic review. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3278.
94.
Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, Nikol S, Nehler M, Sillesen H, Aboyans V, Patel MR. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020 Nov 6;315:10-17.
95.
Nikol S, Mathias K, Olinic DM, Blinc A, Espinola-Klein C. Aneurysms and dissections – What is new in the literature of 2019/2020 – a European Society of Vascular Medicine annual review.
Vasa. 2020 Aug;49(Suppl 104):1-36.
96.
Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, Katsanos K, Mills JL, Nikol S, Reekers J, Venermo M, Zierler RE, Schaper NC, Hinchliffe RJ. Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3277.
97.
Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, Katsanos K, Mills JL, Nikol S, Reekers J, Venermo M, Zierler RE, Hinchliffe RJ, Schaper NC. Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: A systematic review. .Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3279.
98.
Brodmann M, Wissgott C, Brechtel K, Nikol S, Zeller T, Lichtenberg M, Blessing E, Gray W; TOBA III Investigators. Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results.
J Vasc Surg. 2020 Nov;72(5):1636-1647.
Kredteck A, Ranft J, Gerss J, Nikol S. Cross-Cultural Adaptation and Validation of the German Version of the Edinburgh Claudication Questionnaire. VASA, submitted.
Stypmann J, Welp H, Reiners D, Spieker T, Rothenburger M, Vahlhaus C, Bruch C, Wichter T, Erren M, Scheld HH, Baba HA, Wohlschläger J, Schmid C, Nikol S. Gender mismatch in heart transplantation is associated with increased numbers of severe rejections and shorter long-term survival. submitted.
Hasib L*, Klocke R*, Kuhlmann M, Tian W, Scobioala S, Milting H, El-Banayosy A, Tenderich G, Nikol S. Expression of thrombospondin-1 and -2 in infarcted and failing mouse and human myocardium. submitted.
Books, book chapters, congress proceedings and reviews
Höfling B, Gonschior P, Nikol S, Bauriedel G, Welsch U, Nerlich A. Pathophysiology and pathobiochemsitry of restenosis). Pathophysiologie und Pathobiochemie der Rezidivstenose. Zeitschrift für Kardiologie. 83:313-318, 1994
Nikol S, Huehns TY. Medicine and nursing. Nurses’ role is narrowing in Germany. British Medical Journal. 311:873, 1995
Nikol S, Höfling B. Regulation of smooth muscle cell proliferation and possible role in preventing restenosis post-angioplasty. Wiener Klinische Wochenschrift. 13:379-389, 1995
Nikol S, Huehns TY, Gonschior P, Höfling B. Myointimal Hyperplasia. Critical Ischaemia. 5:15-27, 1995
Höfling B, Huehns TY, Gonschior P, Nikol S. (Drug and instrumental approaches for prevention of restenosis). Medikamentöse und instrumentelle Therapieansätze zur Restenoseprophylaxe. Zeitschrift für Kardiologie. 84:151-158, 1995
Nikol S. Zwischen Taiji und Herztransplantation. Deutsches Ärzteblatt. 20:1036-1038, 1996
Isner JM, Kearney M, Pickering JG, Leclerc G, Nikol S, Weir L. The Pathology of Restenosis. In: Invasive Cardiology: Current Diagnostic and Therapeutic Issues. Vetrovec G.W., Caballero B.A. (eds.). American Heart Association. Armonk N.Y: Futura Publishing Company. 277-299, 1996
Nikol S, Huehns TY, Höfling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 123:17-31, 1996
Nikol S, Höfling B. Aktueller Stand der Gentherapie: Konzepte, klinische Studien und Zukunftsperspektiven. Deutsches Ärzteblatt. 93: A 2620-2628,1996
Huehns TY, Höfling B, Nikol S. Gene therapy for restenosis: Principles and potential. Interventional Cardiology Monitor. 3:33-39, 1996
Nikol S, Huehns TY, Höfling B. Novel uses and potential for calcium antagonists in revascularization. European Heart Journal. 18:A105-109, 1997
12.
Höfling B, Gonschior P, Esin S, Nikol S. Das Problem der Restenose nach Angioplastie: Klinische Bedeutung, Pathobiologie, zukünftige Entwicklung zur Suppression der Rezidivstenose. Der Internist. 38: 31-43, 1997
13.
Nikol S. Aktueller Stand der Gentherapie. Schlußwort. Deutsches Ärzteblatt. 15: A996-A997,1997
14.
Nikol S. Possible uses of gene therapy in reducing coronary restenosis. Editorial. Heart. 78:426-428, 1997
15.
Nikol S. Molecular biology and postangioplasty restenosis (hebräisch). Cardiology Update 16: 18-24, 1997
16.
Nikol S, Höfling B. A génterápia jelenlegi állása: Koncepciók, klinikal vizsgálatok és a jövö kilátásai. (Aktueller Stand der Gentherapie: Konzepte, klinische Studien und Zukunftsperspektiven) (ungarisch). Association of the Hungarian Medical Societies (MOTESZ) Magazin 3/1997.
17.
Nikol S, Maier A, Krauß E, Höfling B, Huehns TY. Current biotechnological approaches to the prevention of restenosis. BioDrugs. 9:375-388, 1998
18.
Nikol S. Gene therapy for restenosis: Progress or frustration? Journal of Invasive Cardiology. 10:506-514, 1998
19.
Nikol S, Höfling B. Restenose nach Angioplastie: Aktueller Stand und Zukunftsperspektiven. Der Bayerische Internist. 18:115-124, 1998.
20.
Nikol S, Huehns TY. Gene therapy for cardiovascular diesease. Cardiología al Día. 1:31-33, 1998.
21.
Fenger H, Raem A, Sperlich C, Weissauer W, Thaler CJ, Badura B, Gilessen A, Kerres A, Grevers G, Nikol S, Bannert C, Winter S. Standardmeldebogen zur Qualitätssicherung bei Patientenereignissen. Verlag C.H. Beck, München. 1999.
22.
Armeanu S, Nikol S. Literature Alert for Gene Therapy of Cardiovascular Disorders. In Current Cardiology. V. Fuster, J.M. Isner (Hrsg.). 1(4):261-262, 1999
23.
Nikol S. American Heart Association 72nd Scientific Sessions Atlanta, 7. – 10. November 1999. PTCA Aktuell Newsletter April 2000. 14: 34-37, 2000.
Nikol S. Aktueller Stand der Gentherapie. In Handbuch der Molekularen Medizin, Band 7: Monogen bedingte Erbkrankheiten (Teil 2). D. Ganten und K. Ruckpaul (Hrsg.). Springer Verlag ISBN 3-540-65530-1. 297-374, 2000.
25.
Nikol S, Höfling B. Restenose nach Angioplastie – Interventionsmöglichkeiten. In: Interventionelle Kardiologie, Angiologie und Kardiovaskularchirurgie. Hombach V (Hrsg.). Schattauer Verlag ISBN 3-7945-1931-0. 361-373, 2001.
26.
Engelmann MG, Nikol S. Therapeutische Angiogenese peripherer Arterien. Herz. 25:600-610, 2000.
27.
Nikol S,. Hallek M. Kapitel 17: Therapie mit Genen; Erfahrungen und Zukunftsperspektiven 10 Jahre nach klinischer Einführung. In GenMedizin. A. Raem, R. Braun, H. Fenger, M. Michaelis, S. Nikol, S. Winter, (Hrsg.). Springer Verlag ISBN 3-540-67393-8. 267-331, 2000.
28.
Nikol S, Engelmann MG. Neoangiogenese bei koronaren und peripheren ischämischen Gefäßerkrankungen. Herzmedizin. 17:167-179, 2000.
29.
Nikol S. Thromboserisiken für Frauen im kardiovaskulären Bereich. Proceedings des 27. Wissenschaftlichen Kongresses des Deutschen Ärztinnenbundes. pp 49-63, 2001.
30.
Nikol S, Engelmann MG. Stand der Gentherapie und lokalen Medikamentenapplikation im kardiovaskulären Bereich. In: Molekulare Medizin, Mikrotherapie und High-Tech-Operationen im 21. Jahrhundert. Mau, Mau Laubach (Hrsg.) Springer-Verlag. ISDN 3-540-42321-4. pp135-179, 2001.
31.
Nikol S, Engelmann MG. Aktueller Stand der Gentherapie und lokalen Medikamentenapplikation in der Kardiologie (Teil I). Kardiologie Assistenz. 13(2):6-8, 2001.
32.
Nikol S, Engelmann MG. Aktueller Stand der Gentherapie und lokalen Medikamentenapplikation in der Kardiologie (Teil II). Kardiologie Assistenz. 13(3):6-7, 2001.
33.
Nikol S, Engelmann MG. Aktueller Stand der Gentherapie und lokalen Medikamentenapplikation in der Kardiologie (Teil III). Kardiologie Assistenz. 13 (4):7-10, 2001.
34.
Engelmann MG, Nikol S. Therapeutische Neoangiogenese: Alternative oder adjuvante Therapieoption bei der Behandlung fortgeschrittener koronarer und peripherer ischämischer Gefäßerkrankungen. Deutsche Medizinische Wochenschrift. 126:1053-1058, 2001.
35.
Nikol S. Angiogenesis and cardiovascular disease: How long will it last and how can we stop it? Dialogues. 6:190-196, 2001.
36.
Nikol S, Engelmann MG. Neoangiogenese bei koronaren und peripheren ischämischen Gefäßerkrankungen. Der Bayerische Internist. 21:84-101, 2001.
37.
Nikol S, Huehns TY. Preclinical and clinical experience in vascular gene therapy: Advantages over conservative/standard therapy. The Journal of Invasive Cardiology. 13:333-338, 2001.
38.
Engelmann MG, Nikol S. Therapeutische Angiogenese als Behandlungsmöglichkeit bei kritischer peripherer Ischämie. In: Interventionelle Gefäßtherapie, Kapitel VI: Weit fortgeschrittene periphere Arteriosklerose. C. Vallbracht, F.J. Roth, A.L. Strauss (Hrsg.). Dr. Dietrich Steinkopff Verlag, Darmstadt. ISDN 3-7985-1278-7. pp 363-373, 2002.
39.
Nikol S. Potentielle Zukunft der Anti-Aging Therapie: Gentherapie: Grundlagen, präklinische und klinische Studien, Zukunftsperspektiven. Verhandlungsband der 1. Konferenz der Deutschen Gesellschaft für Anti-Aging Medizin (GSAAM). Congress Compact Verlag. pp 131-154, 2002.
40.
Nikol S, Middendorf K. Thromboembolie- und Arteriosklerose-Risiko bei Frauen. Zeitschrift für Kardiologie. 91:523-535, 2002.
41.
Nikol S. Sind Frauen anders? Teil I: Thrombose- und Embolierisiko bei Frauen. Kardiologie Assistenz.14 (2):6-8, 2002.
Nikol S. Sind Frauen anders? Teil II: Arterioskleroserisiko bei Frauen. Kardiologie Assistenz.14 (3):7-10, 2002.
43.
Shimizu M, Pelisek P, Nikol S. Vasculogenesis and angiogenesis: Regulation in the arterial tree depends on the differential developmental origin. Current Medicinal Chemistry. 9:1619-1630, 2002.
Nikol S, Engelmann MG. Experimentelle und klinische Ergebnisse zur Therapie mit Wachstumsfaktoren in der Kardiologie. PTCA Aktuell. 23: 37-49, 2003.
45.
Nikol S, Lawall H, Diehm C. Kritische Extremitätenischämie: Erste große Phase II-Studie zur Gentherapie – Ist Ihr Patient ein Kandidat für die Teilnahme? Cardiovasc. 3 (7), 28-29, 2003.
46.
Engelmann MG, Nikol S. Impact of Chlamydia pneumoniae and latest insights in whether or not prevention using antibiotics makes sense. E-journal of the European Society of Cardiology. Volume 2 No7, 2003
47.
Scobioala S, Klocke R, Kuhlmann M, Michel G, Nikol S. Proteomic analysis: State of the art and its application in cardiovasacular research. Current Medicinal Chemistry. 11:3203-3218, 2004.
48.
Pelisek J, Shimizu M, Nikol S. Differential developmental origin of arteries: Impact on angiogenesis and arteriogenesis. Medical Chemistry Reviews-Online. 1(3), 317-326, 2004.
49.
Nikol S. Neue Therapieansätze: Therapie der pAVK im Endstadium. MedReview. 6:4-8, 2004
50.
Nikol S, Pham BH, Lawall H, Diehm C. Gentherapie als neue Behandlungsmethode: jetzt auch als Ergänzung zur herkömmlichen Therapie der Claudicatio intermittens. Cardiovasc. 4 (8):40-41, 2004.
51.
Nikol S. Post-meopausal hormone replacement therapy – what has been left? E-journal of the European Society of Cardiology. Volume 3 No10, 2004
52.
Nikol S, Lawall H, Diehm C. Talisman™: Erste europäische Gentherapiestudie zur Behandlung von chronischen Ulzera der Füße und Unterschenkel (Ulcus cruris arteriosum) bei pAVK. Cardiovasc. 1:22-23, 2004.
53.
Nikol S, Middendorf K. Thromboembolism and coronary heart disease: In which aspects are women different? In: Focus on Hormone Replacement Research. M.I Portallis (Ed.) Nova Science Publishers. pp59-84, 2005.
54.
Nikol S, Höfling B, Granada J, Pels K, Huehns TY. The needle catheter. In: Handbook of Local Drug Delivery, E. Camenzind, I. De Scheerder (eds). Martin Dunitz Publishers. pp67-78, 2005.
55.
Nikol S. Therapeutic Angiogenesis in the heart – where do we stand today? E-journal of the European Society of Cardiology. Volume 4 No3, 2005
56.
Nikol S. Molekulare Medizin: Konzepte, klinische Studien und Zukunftsperspektiven. In: Handbuch Geratrie und Gerontologie. Fenger, Kerres, Nikolaus, Raem, Rychlik und Vömel (Hrsg.). Deutsche Krankenhaus VerlagsGesellschaft mbH. pp. 333-339, 2005
57.
Nikol S, Engelmann MG. Kardiovaskuläre Gentherapie: Erste präklinische und klinische Erfahrungen. In: Handbuch Geratrie und Gerontologie. Fenger, Kerres, Nikolaus, Raem, Rychlik und Vömel (Hrsg.). Deutsche Krankenhaus VerlagsGesellschaft mbH. pp. 341-350, 2005
58.
Baumgartner I, Nikol S. Clinical efficacy of therapeutic angiogenesis with intramuscular NV1FGF: results from a randomized, controlled trial. Charing Cross Symposium. in press
58.
Klocke R, Hasib L, Nikol S. Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-angioplasty. Recent Patent Reviews on Cardiovascular Drug Discovery. 1:57-66, 2006
59.
Nikol S. Sind Frauen anders? Herz- und Gefässerkrankungen bei Frauen: Diagnose, Therapie und Prognose. Herzzentrum Journal Münster. 2:18-20, 2006.
60.
Scobioala S, Michel G, Nikol S. Chapter 2: Proteomics: State of the art and its relevance for gene therapy. In: Gene Therapy. Cardiovascular Research: New Technologies, Methods & Applications. G. Pasterkamp, D.P.V. de Kleijn (Hrsg.). Kluwer Academic/Plenum Publishers. pp. 45-64, 2006.
61.
Klocke R, Scobioala S, Nikol S. Chapter 3: Cardiovascular proteomics. In: Gene Therapy. Cardiovascular Research: New Technologies, Methods & Applications. G. Pasterkamp, D.P.V. de Kleijn (Hrsg.). Kluwer Academic/Plenum Publishers. pp. 65-74, 2006.
62.
Nikol S, Kuhlmann M. Mobilisierung von Stammzellen bei Herzkreislauferkrankungen: Verbesserung von Vaskularisierung, Herzfunktion und Rhythmusstörungen (Mobilization of stem cells in cardiovascular disease. Improvement of vascularization, cardiac function and arrhythmias). Medizinische Klinik. 101, Suppl 1:190-192, 2006
63.
Schäbitz WR, Nikol S, Schneider A. Granulocyte colony-stimulating factor and acute myocardial infarction. Developing G-CSF for the treatment of cardiovascular disease: A view from the stroke field. JAMA. 296:1967-1968, 2006.
64.
Nikol S, Diehm C. WALK-Gentherapiestudie für Claudicatio-Patienten. Cardiovasc. 6 (8): 57, 2006.
65.
Nikol S. Viral or non-viral angiogenesis gene transfer – New answers to old questions. Cardiovasc Research. 73:443-5. 2007.
66.
Klocke R*, Tian W*, Kuhlmann M*, Nikol S. Surgical animal models of heart failure related to coronary heart disease. Cardiovascular Research. 74:29–38, 2007.
*die Autoren trugen zu gleichen Anteilen bei
67.
Nikol S. Frauenherzen schlagen anders. In Gefässmedizin.net (Hrsg. Espinola-Klein C und Kröger K). Supplement 1, pp22-31, 2007.
68.
69.
Nikol S. Komplikationsmanagement: Thrombosen und Embolien. In Raschke & Rüter (Hrsg.) Altertraumatologie. Elsevier. im Druck
70.
Nikol S. Gen- und Stammzelltherapie der peripheren arteriellen Verschlusskrankheit. Clinical Research in Cardiology Supplements 2:IV/30 –IV/37, 2007.
71.
Nikol S, Middendorf K. Thromboembolie- und Arteriosklerose-Risiko bei Frauen. Prof. Friedrich, Institut für Genetik, Aarhus Universität, Dänemark. im Druck
72.
Nikol S. Zwischen Taiji und Herztransplantation – Chinas Gesundheitswesen. In Wie krank ist unser Gesundheitswesen – Das Gesundheitswesen in Deutschland und Europa an der Schwelle zum 21. Jahrhundert. Verschiedene Gesundheitswesen dieser Welt. G. Heiss (Hrsg.). Edition Kunsthäusle. Im Druck
Nikol S. Therapeutic angiogenesis for peripheral artery disease – Gene Therapy. VASA. 36:165-173, 2007.
74.
Kuhlmann M, Nikol S. Therapeutic angiogenesis for peripheral artery disease – Cytokine Therapy. VASA. 36:253-260, 2007
Lachmann N, Nikol S. Therapeutic angiogenesis for peripheral artery disease – Stem cell therapy. VASA. 36:241-251, 2007
77.
78.
Nikol S. Lokale Gentherapie zur Prävention der Restenose nach PTA: Alternative zu Sirolimus und Paclitaxel. Vasomed. 19 (Supplement Bd 4):5-6, 2007.
79.
Nikol S. Lokale Gentherapie soll Restenosen verhindern. CardioNews. 10:p 1 + 12, 2007.
80.
Klocke R, Kuhlmann M, Scobioala S, Schäbitz WR, Nikol S. Granulocyte Colony-Stimulating Factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Current Medicinal Chemistry. 15(9):968-77, 2008.
81.
Nikol S. Gene therapy for coronary and peripheral artery disease. Expert Opinion on Therapeutic Patents. 18:903-927, 2008.
82.
Nikol S. Zellbasierte Therapie der pAVK: Wie weit sind wir? Vasomed 20:137, 2008.
83.
Nikol S. Gene therapy of cardiovascular disease. Current Opinion in Molecular Therapeutics. 10:479-492, 2008.
Nikol S. Zellbasierte Therapie der pAVK: Wie weit sind wir? Current Congress. 5, 2008.
85.
Baumgartner I, Nikol S. Clinical efficacy of therapeutic angiogenesis with intramuscular NV1FGF: results from a randomized, controlled trial. Charing Cross Symposium. 2009
86.
Nikol S. [Therapeutic angiogenesis using gene transfer and stem cell therapy in peripheral artery disease]. Dtsch Med Wochenschr. 2011;136(14):672-4.
87.
Sedighiani F, Nikol S. Gene therapy in vascular disease. Surgeon. 2011;9(6):326-35.
88.
Nikol S. Stammzelltherapie in der Gefäßtherapie. Zentralbl Chir. 2011;136(5):399-403.
89.
Nikol S. Perkutane transluminale Angioplastie (PTA) der Arteria femoralis superficialis -State of the Art. Phlebologie. 2012
90.
Nikol S (Hrsg.). Buch Extremitätenischämie – Diagnose und Therapie. Unimed-Verlag. 2012.
91.
Nikol S. Debate: Endovascular techniques must be taught with interdisciplinary collaboration. For the motion. Proceedings. Charing Cross Symposium. 2012.
92.
Nikol S. Perkutane transluminale Angioplastie (PTA) der Arteria femoralis superficialis -State of the Art. Phlebologie. 2012
93.
Nikol S. Regenerative Therapie der peripheren arteriellen Verschlußkrankheit. In: Gefäßmedizin: Therapie und Praxis (Hrsg. Ciaarek, Kröger, Santosa und Zeller). ABW Verlag. Neuauflage 2013
Eid A, Nikol S. Endovascular management of patients with peripheral vascular disease with cardiovascular multi-morbidity. Cor et Vasa., 60 (1), e35-e41, 2018
95.
Grosser S, Jü-von Lipinski P, Nikol S, Koeppel TA. Der besondere Fall: Tückische Symptome. Hamburger Ärzteblatt 08/2018
96.
Klaus Mathias und Sigrid Nikol. Kranke Gefäße – gefährdetes Herz. Schon erste Anzeichen der „Schaufensterkrankheit“ sind ernst zu nehmen. Herz heute
97.
Xie Z, Ko K, Andresen C, Ateghang B, Nikol S, Schöler H*, Klocke R. The potential of non-embryonic pluripotent stem cells for regenerative therapy of the failing heart. In Vorbereitung.
United Kingdom
Jill Belch, FRCP, MD, OBE, FR(E), FAMedSci.
Jill Belch is a Professor of Vascular Medicine at the University of Dundee, UK, where until January 2016 she was the Research Dean then Co-Dean of the Medical School. She was also NHS Tayside R&D Director for 10 years also to 2016. Further she established and became Co-Director of the Tayside Academic Health Partnership. She is a founder Fellow of the Academy of Medical Science and a Fellow and Council Member of the Royal Society, Edinburgh. She is currently Head of the Institute of Cardiovascular Research. Her research interests centre on cardiovascular disease with especial reference to peripheral arterial disease (PAD), evaluating biomarkers, inflammation, endothelial function and novel treatments. She also has a keen interest in the Microcirculation and is researching environmental issues such as the effects of air pollution on health. Professor Belch is Chair or former Chair of trial steering committees for 19 international multicentre clinical trials of new treatments for vascular disease, and she has authored over 400 publications in peer-reviewed journals. She is Immediate Past President of the UK Section of Vascular Medicine at the Royal Society of Medicine and is currently President of the European Society of Vascular Medicine (ESVM), for whom she also chairs the ESVM Guidelines Committee. She was awarded an OBE in 2016 for Services to Medicine, and the Saltire Outstanding Women of the year in 2019.
